Singapore markets open in 1 hour 34 minutes

Clinuvel Pharmaceuticals Limited (CUV.XA)

Cboe AU - Cboe AU Real-time price. Currency in AUD
Add to watchlist
15.09-0.01 (-0.03%)
At close: 03:59PM AEST
Full screen
Previous close15.10
Bid0.00 x N/A
Ask0.00 x N/A
Day's range14.92 - 15.18
52-week range12.98 - 21.52
Avg. volume20,957
Market capN/A
Beta (5Y monthly)0.74
PE ratio (TTM)32.12
EPS (TTM)0.47
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Photomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors

    DÜSSELDORF, Germany, March 28, 2024 (GLOBE NEWSWIRE) -- Pioneering biopharmaceutical company CLINUVEL yesterday hosted a wide-ranging market briefing discussing its novel drug SCENESSE® (afamelanotide) and the future of photomedicine. Over 70 guests discussed the Company’s unique history and future growth potential at an invitation-only event in Düsseldorf. Managing Director and CEO, Dr Philippe Wolgen shared the Company’s success in establishing profitability over the past seven financial years

  • Simply Wall St.

    Clinuvel Pharmaceuticals (ASX:CUV) shareholders have endured a 50% loss from investing in the stock three years ago

    Investing in stocks inevitably means buying into some companies that perform poorly. Long term Clinuvel Pharmaceuticals...

  • GlobeNewswire

    Malibu shines a light on CLINUVEL’s pioneering work in photomedicine

    MALIBU, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Leading biotech company CLINUVEL last week joined an intimate event bringing together California’s most prolific investors and philanthropists at the Malibu home of Lady Gaga and Michael Polansky. The event, hosted by Lady Gaga and Mr. Polansky, and Sean Parker and Alexandra Parker, shone a light on the groundbreaking work of CLINUVEL, a global biopharmaceutical firm whose cutting-edge melanocortin therapies transform the lives of patients at th